Previous close | 9.11 |
Open | 9.13 |
Bid | 9.23 x 100 |
Ask | 9.28 x 200 |
Day's range | 9.12 - 9.46 |
52-week range | 7.75 - 14.84 |
Volume | |
Avg. volume | 495,349 |
Market cap | 357.242M |
Beta (5Y monthly) | 0.60 |
PE ratio (TTM) | N/A |
EPS (TTM) | -1.60 |
Earnings date | 30 Apr 2024 - 06 May 2024 |
Forward dividend & yield | N/A (N/A) |
Ex-dividend date | N/A |
1y target est | 16.83 |
REDWOOD CITY, Calif., March 15, 2024 (GLOBE NEWSWIRE) -- Pulmonx Corporation (Nasdaq: LUNG) (“Pulmonx” or the “Company”), a global leader in minimally invasive treatments for lung disease, today announced the inducement grant of equity awards to Steve Williamson, its newly-hired President and Chief Executive Officer, in accordance with Nasdaq Listing Rule 5635(c)(4). On March 15, 2024, Pulmonx granted Mr. Williamson (i) 205,286 time-based restricted stock units, which will vest as to 25% of such
Steven Cohen (Trades, Portfolio)'s Point72 Asset Management has recently made a notable addition to its investment portfolio by acquiring additional shares in Pulmonx Corp (NASDAQ:LUNG). The firm now holds a 5.00% stake in Pulmonx Corp, representing 0.04% of its investment portfolio. Steven A. Cohen, the Chairman and CEO of Point72 Asset Management, is a prominent figure in the investment world.
REDWOOD CITY, Calif., February 26, 2024--Pulmonx Corporation (Nasdaq: LUNG) ("Pulmonx" or the "Company"), a global leader in minimally invasive treatments for chronic obstructive pulmonary disease (COPD), today announced the treatment of the first patient in the CONVERT II Pivotal Trial, a multicenter, international study evaluating the safety and effectiveness of the AeriSeal® System in limiting collateral ventilation in severe COPD/emphysema patients. Collateral ventilation is caused by openin